AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aardvark Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.74−0.04 (-1.06%)
Close on Oct 19, 2026
- Market cap
- $81.70M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$9.07 (−70.80%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Aardvark Therapeutics, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$54.27M.
Revenue
$0
TTM Q2 2026
Operating income
-$73.96M
TTM Q2 2026
Free cash flow
-$54.27M
FY2025
EPS, diluted
-$3.21
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $81.70M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.09
- Dividend yield
- –
- Free cash flow yield
- -66.42%
Fundamentals
- Revenue
- $0
- Net income
- -$69.89M
- EPS, diluted
- -$3.21
- Free cash flow
- -$54.27M
- Book value per share
- $3.42
- Diluted shares
- 22M
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Revenue
$0
Operating income
-$73.96M
Net income
-$69.89M
EPS, diluted
-$3.21
Free cash flow
–
Reported periodTrailing twelve months